Catabasis Pharmaceuticals Announces Promotion of Andrew Nichols, Ph.D. to Chief Scientific Officer & Angelika Fretzen to Seni...
October 05 2016 - 8:00AM
Business Wire
Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage
pharmaceutical company, today announced the promotion of Andrew
Nichols, Ph.D. to Chief Scientific Officer and Angelika Fretzen,
Ph.D., to Senior Vice President of Product Development. Dr. Nichols
has more than 25 years of drug development experience, leading
efforts from target discovery through translational research and
early clinical development for pharmaceutical and biotechnology
companies. Dr. Fretzen has 15 plus years of entrepreneurial drug
discovery and development experience.
“Andy and Angelika have provided tremendous value to Catabasis
in supporting the development of edasalonexent (CAT-1004) in
Duchenne muscular dystrophy and also the advancement of our
pipeline in rare diseases,” said Jill C. Milne, Ph.D., Chief
Executive Officer of Catabasis. “We look forward to their further
leadership of and contributions to Catabasis.”
Dr. Nichols joined Catabasis in 2014 and previously served as
Senior Vice President, Research & Non-Clinical Development.
Prior to joining Catabasis, Dr. Nichols was Associate Vice
President, Cardiometabolic Diseases at Merck Research Labs, leading
drug discovery and early clinical development programs. Prior to
Merck, Dr. Nichols was Vice President of Preclinical Research at
Zafgen, Vice President of Research at Alinea, Vice President of
Drug Discovery Project Leadership at Millennium and Director of the
Alliance Management Group at SmithKline Beecham. He has worked
across multiple therapeutic areas (cardiovascular, metabolic,
oncology and inflammation), utilizing a combination of internal and
external sourcing strategies. He holds his B.Sc. in Pharmacology
from the University of Leeds, England, and his M.Phil. and Ph.D. in
Cardiovascular Pharmacology from the University of Cambridge,
England.
Dr. Fretzen joined Catabasis in 2014 and previously served as
Vice President, Product Development & Program Management. Prior
to joining Catabasis, she was Vice President of Pharmaceutical
Chemistry and Development at Ironwood Pharmaceuticals. Dr. Fretzen
led Pharmaceutical Development and CMC-related aspects of
Ironwood's linaclotide program through the approval as Linzess® in
the US and as ConstellaTM in Canada and Europe. She has been
responsible for discovery and development programs for small
molecules and peptides in a variety of different disease areas.
Prior to joining Ironwood Pharmaceuticals, Dr. Fretzen was an
Alexander von Humboldt Fellow in the Department of Chemistry and
Chemical Biology at Harvard University. She holds a Diploma (M.S.)
in chemistry from the University of Würzburg in Germany and her
Ph.D. in organometallic and synthetic organic chemistry from the
University of Geneva, Switzerland. In addition, Dr. Fretzen has
received an MBA from Suffolk University in Boston.
About CatabasisAt Catabasis Pharmaceuticals, our mission
is to bring hope and life-changing therapies to patients and their
families. Our SMART (Safely Metabolized And Rationally Targeted)
linker drug discovery platform enables us to engineer molecules
that simultaneously modulate multiple targets in a disease. We are
applying our SMART linker platform to build an internal pipeline of
product candidates for rare diseases and plan to pursue
partnerships to develop additional product candidates. For more
information on the Company's drug discovery platform and pipeline
of drug candidates, please visit www.catabasis.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161005005183/en/
Catabasis Pharmaceuticals, Inc.Andrea Matthews,
617-349-1971amatthews@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Sep 2023 to Sep 2024